Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.

In patients with type 2 diabetes, gastric inhibitory polypeptide (GIP) has lost much of its insulinotropic activity. Whether this is similar in first-degree relatives of patients with type 2 diabetes is unknown. A total of 21 first-degree relatives, 10 patients with type 2 diabetes, and 10 control subjects (normal oral glucose tolerance) were examined. During a hyperglycemic "clamp" (140 mg/dl for 120 min), synthetic human GIP (2 pmol. kg(-1). min(-1)) was infused intravenously (30-90 min). With exogenous GIP, patients with type 2 diabetes responded with a lower increment (Delta) in insulin (P = 0.0003) and C-peptide concentrations (P < 0.0001) than control subjects. The GIP effects in first-degree relatives were diminished compared with control subjects (Delta insulin: P = 0.04; Delta C-peptide: P = 0.016) but significantly higher than in patients with type 2 diabetes (P < or = 0.05). The responses over the time course were below the 95% CI derived from control subjects in 7 (insulin) and 11 (C-peptide) of 21 first-degree relatives of patients with type 2 diabetes. In conclusion, a reduced insulinotropic activity of GIP is typical for a substantial subgroup of normoglycemic first-degree relatives of patients with type 2 diabetes, pointing to an early, possibly genetic defect.

[1]  R. Pederson,et al.  Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. , 2001, Diabetes.

[2]  A. de Leiva,et al.  Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test , 2000, Diabetologia.

[3]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[4]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) in first-degree relatives of type 2 diabetic patients , 2000 .

[5]  M. Stumvoll,et al.  Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion , 2000, Diabetologia.

[6]  J. Miyazaki,et al.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Holst,et al.  Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations , 1999, Diabetologia.

[8]  J. Levy,et al.  Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. , 1999, Diabetes.

[9]  S. Kahn,et al.  Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. , 1999, The Journal of clinical endocrinology and metabolism.

[10]  D. Finegood,et al.  A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. , 1998, The Journal of clinical endocrinology and metabolism.

[11]  P. Raskin,et al.  Obesity-independent hyperinsulinemia in nondiabetic first-degree relatives of individuals with type 2 diabetes. , 1998, Diabetes.

[12]  B. Göke,et al.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. , 1998, The Journal of clinical investigation.

[13]  T. Hansen,et al.  Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells , 1998, Diabetologia.

[14]  J. Holst,et al.  Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 , 1998, Pflügers Archiv.

[15]  D. Erkelens,et al.  Insulin Secretion in Normal Glucose-Tolerant Relatives of Type 2 Diabetic Subjects: Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests , 1998, Diabetes Care.

[16]  G. Volpicelli,et al.  Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. , 1998, Molecular genetics and metabolism.

[17]  I. Vauhkonen,et al.  Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. , 1998, The Journal of clinical investigation.

[18]  J. Holst,et al.  Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[19]  P. Halban,et al.  Release of Incompletely Processed Proinsulin Is the Cause of the Disproportionate Proinsulinemia of NIDDM , 1997, Diabetes.

[20]  J. Holst,et al.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.

[21]  M. Walker,et al.  Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families , 1997, Diabetologia.

[22]  J. Holst,et al.  The pathogenesis of NIDDM involves a defective expression of the GIP receptor , 1997, Diabetologia.

[23]  K. Tsuda,et al.  Identification of Two Missense Mutations in the GIP Receptor Gene: A Functional Study and Association Analysis with NIDDM: No Evidence of Association with Japanese NIDDM Subjects , 1996, Diabetes.

[24]  T. Usdin,et al.  Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.

[25]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[26]  B. Göke,et al.  Molecular cloning, functional expression, and signal transduction of the GIP‐receptor cloned from a human insulinoma , 1995, FEBS letters.

[27]  P. Froguel,et al.  Cloning, Functional Expression, and Chromosomal Localization of the Human Pancreatic Islet Glucose-Dependent Insulinotropic Polypeptide Receptor , 1995, Diabetes.

[28]  B. Singh,et al.  A simple measure of insulin resistance , 1995, The Lancet.

[29]  G. Dailey,et al.  Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. , 1995, JAMA.

[30]  J. Brown,et al.  Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. , 1995, The American journal of physiology.

[31]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[32]  E. Ravussin,et al.  Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. , 1993, The New England journal of medicine.

[33]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[34]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[35]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[36]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[37]  M. Nauck,et al.  Gut hormones and diabetes mellitus. , 1992, Diabetes/metabolism reviews.

[38]  J. Leahy,et al.  β-Cell Dysfunction Induced by Chronic Hyperglycemia: Current Ideas on Mechanism of Impaired Glucose-Induced Insulin Secretion , 1992, Diabetes Care.

[39]  S. Kahn,et al.  Hyperproinsulinemia and Amyloid in NIDDM: Clues to Etiology of Islet β-Cell Dysfunction? , 1989, Diabetes.

[40]  B. Göke,et al.  Signal transmission after GLP-1(7-36)amide binding in RINm5F cells. , 1989, The American journal of physiology.

[41]  L. Groop,et al.  Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. , 1989, The New England journal of medicine.

[42]  G. Reaven,et al.  Insulin resistance and hypertriglyceridemia in nondiabetic relatives of patients with noninsulin-dependent diabetes mellitus. , 1989, The Journal of clinical endocrinology and metabolism.

[43]  S. Haffner,et al.  Increased insulin concentrations in nondiabetic offspring of diabetic parents. , 1988, The New England journal of medicine.

[44]  S. O’Rahilly,et al.  Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. , 1988, The New England journal of medicine.

[45]  T. Krarup.  Immunoreactive gastric inhibitory polypeptide. , 1988, Endocrine reviews.

[46]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[47]  S. Madsbad,et al.  Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. , 1987, Metabolism: clinical and experimental.

[48]  S. O’Rahilly,et al.  BETA-CELL DYSFUNCTION, RATHER THAN INSULIN INSENSITIVITY, IS THE PRIMARY DEFECT IN FAMILIAL TYPE 2 DIABETES , 1986, The Lancet.

[49]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[50]  R. DeFronzo,et al.  Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. , 1985, The Journal of clinical investigation.

[51]  J. Halter,et al.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1984, The Journal of clinical investigation.